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Following publication of the data presented by von Minckwitz
and colleagues [1] it has been brought to our attention that
some patients should be scored differently. Stable disease
was seen in three of the eighteen patients instead of two of
the eighteen patients: one patient with transitional cell carci-
noma treated at 4 µg/kg scFv(FRP5)-ETA per day, and two
breast cancer patients treated at 4 and 12.5 µg/kg
scFv(FRP5)-ETA per day. Disease progression occured in 9
of the eighteen patients evaluated (see corrected Table 2
overleaf). This does not affect the conclusions of our study. In
addition we would like to correct the following errors: patient
IDs for patients U01 and U02 in the original Table 2 were
interchanged. In addition, patient N03 had a grade 3
elevation of gamma-glutamyl transferase, and not grade 2
(see corrected Table 2 overleaf).
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Table 2
Study summary
Dose level  Dose-limiting Neutralizing  Clinical 
Patient (µg/kg) Course of therapy Toxicities ≥grade 1 toxicity antibodies response
N01 2 According to plan GGT grade 2 No No Progression
U01 2 Stopped on day 10 Cholestasis due to liver metastasisa No n.d. n.d.
U02 2 According to plan None No n.d. Progression
N03 4 According to plan GGT grade 2 No No Stable disease
N04 4 According to plan ALT grade 1 No No Stable disease
N05 4 According to plan Hemoglobin grade 3a No No Progression
N06 10 According to plan ALT grade 2, AST grade 1 No + Progression
N07 10 According to plan ALT/AST grade 1, GGT grade 3 No No Progression
U03 10 According to plan Fever and dyspnoeb No ++ n.d.c
N13 12.5 According to plan ALT grade 1, GGT grade 2, AP grade 1 No No Progression
N14 12.5 Stopped on day 8 ALT/AST grade 3, GGT grade 2, LDH grade 1 Yes n.d. n.d.
N15 12.5 According to plan ALT grade 2, AST grade 1, AP grade 2 No + Progression
N17 12.5 According to plan ALT/AST grade 2 No No Progression
U04 12.5 According to plan Dyspnoe No No n.d.c
U05 12.5 According to plan None No ++ Stable disease
N09 20 According to plan ALT/AST grade 2 No +++ Progression
N10 20 Stopped on day 8 ALT grade 4, AST grade 3, GGT grade 2 Yes n.d. n.d.
N12 20 Stopped on day 8 ALT grade 3, AST grade 2 Yes n.d. n.d.c
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; n.d., not determined. 
aCausal relationship with study drug unlikely. 
bPatient U03 developed fever and dyspnoe after therapy on day 23, which was resolved with antibiotics; the patient died on day 40, causal
relationship with study drug unlikely. 
cClinical signs of activity while on therapy including healing of cutaneous lesion (U03, U04), size reduction of lymph node metastasis (U03), and
inflammatory response and softening of large tumor mass (N12).